187 related articles for article (PubMed ID: 32795465)
1. Chromosome 3p loss of heterozygosity and reduced expression of H3K36me3 correlate with longer relapse-free survival in sacral conventional chordoma.
Zhu GG; Ramirez D; Chen W; Lu C; Wang L; Frosina D; Jungbluth A; Ntiamoah P; Nafa K; Boland PJ; Hameed MR
Hum Pathol; 2020 Oct; 104():73-83. PubMed ID: 32795465
[TBL] [Abstract][Full Text] [Related]
2. Genomic aberrations frequently alter chromatin regulatory genes in chordoma.
Wang L; Zehir A; Nafa K; Zhou N; Berger MF; Casanova J; Sadowska J; Lu C; Allis CD; Gounder M; Chandhanayingyong C; Ladanyi M; Boland PJ; Hameed M
Genes Chromosomes Cancer; 2016 Jul; 55(7):591-600. PubMed ID: 27072194
[TBL] [Abstract][Full Text] [Related]
3. High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis.
Diaz RJ; Guduk M; Romagnuolo R; Smith CA; Northcott P; Shih D; Berisha F; Flanagan A; Munoz DG; Cusimano MD; Pamir MN; Rutka JT
Neoplasia; 2012 Sep; 14(9):788-98. PubMed ID: 23019410
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.
Zhang K; Chen H; Zhang B; Sun J; Lu J; Chen K; Yang H
Int J Clin Exp Pathol; 2015; 8(1):608-14. PubMed ID: 25755752
[TBL] [Abstract][Full Text] [Related]
5. Clonality studies in sacral chordoma.
Klingler L; Trammell R; Allan DG; Butler MG; Schwartz HS
Cancer Genet Cytogenet; 2006 Nov; 171(1):68-71. PubMed ID: 17074594
[TBL] [Abstract][Full Text] [Related]
6. Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute.
Yang Y; Niu X; Li Y; Liu W; Xu H
Eur Spine J; 2017 Jul; 26(7):1910-1916. PubMed ID: 27942938
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in the operative management of dedifferentiated sacral chordomas.
Kayani B; Sewell MD; Hanna SA; Saifuddin A; Aston W; Pollock R; Skinner J; Molloy S; Briggs TW
Neurosurgery; 2014 Sep; 75(3):269-75; discussion 275. PubMed ID: 24867206
[TBL] [Abstract][Full Text] [Related]
8. Skull base chordomas: clinical outcome in a consecutive series of 45 patients with long-term follow-up and evaluation of clinical and biological prognostic factors.
Boari N; Gagliardi F; Cavalli A; Gemma M; Ferrari L; Riva P; Mortini P
J Neurosurg; 2016 Aug; 125(2):450-60. PubMed ID: 26745472
[TBL] [Abstract][Full Text] [Related]
9. Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1.
Rinner B; Froehlich EV; Buerger K; Knausz H; Lohberger B; Scheipl S; Fischer C; Leithner A; Guelly C; Trajanoski S; Szuhai K; Liegl B
Int J Oncol; 2012 Feb; 40(2):443-51. PubMed ID: 22002331
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study.
Longoni M; Orzan F; Stroppi M; Boari N; Mortini P; Riva P
Neuro Oncol; 2008 Feb; 10(1):52-60. PubMed ID: 18094369
[TBL] [Abstract][Full Text] [Related]
11. Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization.
Yang H; Zhu L; Ebraheim NA; Liu X; Castillo S; Tang T; Liu J; Cui H
Spine J; 2009 Dec; 9(12):972-80. PubMed ID: 19800296
[TBL] [Abstract][Full Text] [Related]
12. Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.
Kitamura Y; Sasaki H; Kimura T; Miwa T; Takahashi S; Kawase T; Yoshida K
J Neuropathol Exp Neurol; 2013 Sep; 72(9):816-23. PubMed ID: 23965741
[TBL] [Abstract][Full Text] [Related]
13. HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas.
Jäger D; Barth TFE; Brüderlein S; Scheuerle A; Rinner B; von Witzleben A; Lechel A; Meyer P; Mayer-Steinacker R; Baer AV; Schultheiss M; Wirtz CR; Möller P; Mellert K
Sci Rep; 2017 May; 7(1):2032. PubMed ID: 28515451
[TBL] [Abstract][Full Text] [Related]
14. Atypical Notochordal Cell Tumors: A Series of Notochordal-derived Tumors That Defy Current Classification Schemes.
Carter JM; Wenger DE; Rose PS; Inwards CY
Am J Surg Pathol; 2017 Jan; 41(1):39-48. PubMed ID: 27819871
[TBL] [Abstract][Full Text] [Related]
15. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.
Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A
Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328
[TBL] [Abstract][Full Text] [Related]
16. [Chordoma].
George B; Bresson D; Bouazza S; Froelich S; Mandonnet E; Hamdi S; Orabi M; Polivka M; Cazorla A; Adle-Biassette H; Guichard JP; Duet M; Gayat E; Vallée F; Canova CH; Riet F; Bolle S; Calugaru V; Dendale R; Mazeron JJ; Feuvret L; Boissier E; Vignot S; Puget S; Sainte-Rose C; Beccaria K
Neurochirurgie; 2014 Jun; 60(3):63-140. PubMed ID: 24856008
[TBL] [Abstract][Full Text] [Related]
17. What Are the Conditional Survival and Functional Outcomes After Surgical Treatment of 115 Patients With Sacral Chordoma?
Ji T; Guo W; Yang R; Tang X; Wang Y; Huang L
Clin Orthop Relat Res; 2017 Mar; 475(3):620-630. PubMed ID: 26975382
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite instability in sacral chordoma.
Klingler L; Shooks J; Fiedler PN; Marney A; Butler MG; Schwartz HS
J Surg Oncol; 2000 Feb; 73(2):100-3. PubMed ID: 10694646
[TBL] [Abstract][Full Text] [Related]
19. Chordoma: the nonsarcoma primary bone tumor.
Chugh R; Tawbi H; Lucas DR; Biermann JS; Schuetze SM; Baker LH
Oncologist; 2007 Nov; 12(11):1344-50. PubMed ID: 18055855
[TBL] [Abstract][Full Text] [Related]
20. Sacral chordoma with unusual posterior radiographic presentation.
Coombs RJ; Coiner L
Skeletal Radiol; 1996 Oct; 25(7):679-81. PubMed ID: 8915056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
